Chronic Lymphocytic Leukemia (CLL) is a common hematologic malignancy characterized by the accumulation of mature B lymphocytes in the blood, bone marrow, and lymphoid tissues. Historically, the backbone of CLL therapy has been fludarabine-based regimens for fit patients. However, the landscape of CLL treatment has transformed with the emergence of targeted agents, such as B-cell receptor signaling inhibitors and BCL-2 inhibitors. This article reviews the impact of targeted agents on the survival outcomes of CLL patients who are deemed fit for fludarabinebased therapy. It examines clinical trials, real-world evidence, and expert opinions to provide insights into the evolving treatment paradigms and the implications for clinical practice.
HTML PDFShare this article
Journal of Bioanalysis & Biomedicine received 3099 citations as per Google Scholar report
